MS Expert Urges Recruitment of MInorities to Phase 3 Clinical Trials


Because multiple sclerosis (MS) presentation and progression course can be very different between people of African ancestry and Caucasians, the recruitment of minorities to Phase 3 clinical trials is of particular importance.

Researchers in the MS field and the general MS community should make a greater effort to improve the recruitment of minorities to clinical trials to better understand “how drugs perform in such diverse groups,” Jay Avasarala, MD, PhD, a neurologist specializing in MS and neuroimmunology at U.K. HealthCare’s Kentucky Neuroscience Institute, wrote in an editorial published in CNS Spectrums.

The editorial is titled “FDA-approved drugs for multiple sclerosis have no efficacy or disability data in non-Caucasian patients.”

The number of therapies under development…

Read More


320ro

Comments

comments